SOUTH PLAINFIELD, N.J., Oct. 29, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its Strategies to Realize Innovation, Vision and Empowerment (STRIVE) Awards program to provide funding to nonprofit organizations serving the cystic fibrosis (CF) community by developing unique programs that will raise awareness, increase diagnosis of this genetic disease and further support the needs of the CF community. This is the first STRIVE Awards program focused on CF. Earlier this year PTC launched its first-ever STRIVE Awards program focused on Duchenne muscular dystrophy.
“We are pleased to launch the STRIVE Awards for cystic fibrosis and look forward to the opportunity to support the community in their efforts to serve patients,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. “We respect and value the important services provided by patient advocacy groups to individuals and families affected by this rare disease. Through STRIVE we want to encourage groups across the world to pursue novel and creative programs that will make meaningful contributions and advancements for the community.”